Safety and efficacy of a proteolytic enzyme for enzymatic burn débridement: A preliminary report

Lior Rosenberg, Oren Lapid, Alex Bogdanov-Berezovsky, Ronen Glesinger, Yuval Krieger, Eldad Silberstein, Amiram Sagi, Keith Judkins, Adam J. Singer

Research output: Contribution to journalArticlepeer-review

109 Scopus citations


A prospective, non-comparative study design was used to describe our experience with a bromelain-derived debriding agent, Debridase, in 130 patients with 332 deep second degree and third degree burns treated between 1984 and 1999. Debridase was applied after saturating the burns with a moist dressing for 2-24 h. Debridase was applied for a period of 4 h under an occlusive dressing. Mean patient age was 18.6 ± 19.3, 42 (32.3%) were female, and 63 (48.5%) were children under age 18. Most burns were small. Debridase was applied once in 241 (72.6%) of the 332 wounds, twice in 67 (20.18%) cases, three times in 12 (3.61%) cases, and four times in 2 (0.6%) cases. The percentage débridement by number of applications was 89 ± 21% for a single application, 77 ± 27% for two, and 62 ± 27% for three Debridase applications, respectively. There were no significant adverse events. The availability of a fast acting, reliable and complication-free enzymatic debriding agent may open new horizons and provide a new treatment modality for burns.

Original languageEnglish
Pages (from-to)843-850
Number of pages8
Issue number8
StatePublished - 1 Dec 2004
Externally publishedYes


  • Burns
  • Debridase
  • Enzymatic débridement

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Safety and efficacy of a proteolytic enzyme for enzymatic burn débridement: A preliminary report'. Together they form a unique fingerprint.

Cite this